Related Experiment Video

Updated: Feb 21, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

8.2K

Current treatment of HER 2+ metastatic breast cancer

Russell Burcombe1

  • 1Consultant Clinical Oncologist, Kent Oncology Centre, Maidstone & Tunbridge Wells NHS Trust.

British Journal of Nursing (Mark Allen Publishing)
|October 6, 2017
PubMed

Insights

HER2-positive breast cancer outcomes have significantly improved due to targeted therapies. This summary reviews the evidence on anti-HER2 treatments, highlighting their transformative impact on patient prognosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • HER2-positive breast cancer historically presented a poor prognosis.
  • The HER2 receptor plays a crucial role in cancer cell growth and proliferation.

Purpose of the Study:

  • To summarize the current evidence on anti-HER2 therapies.
  • To highlight the impact of targeted molecular therapies on HER2-positive breast cancer outcomes.

Main Methods:

  • Literature review of studies on anti-HER2 therapies.
  • Analysis of clinical trial data and real-world evidence.

Main Results:

  • Anti-HER2 therapies have revolutionized the treatment landscape.
  • Significant improvements in survival rates and quality of life for patients.

Conclusions:

  • Targeted anti-HER2 therapies are a cornerstone in managing HER2-positive breast cancer.
  • Continued research is essential to further optimize treatment strategies.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K